Affiliation:
1. Department of Endocrinology and Nutrition, Université Catholique de Louvain, Cliniques Universitaires St-Luc, Brussels, Belgium
2. Cystic Fibrosis Unit, Université Catholique de Louvain, Cliniques Universitaires St-Luc, Brussels, Belgium
Abstract
OBJECTIVE—We sought to determine the clinical phenotype of adolescent/adult patients with cystic fibrosis, according to heterozygosity or homozygosity for cystic fibrosis transmembrane regulator (CFTR) ΔF508 mutation, and to analyze their characteristics according to glucose tolerance status.
RESEARCH DESIGN AND METHODS—A total of 76 cystic fibrosis patients with CFTR ΔF508 mutation (33 heterozygous and 43 homozygous) stratified according to normal glucose tolerance (NGT) (n = 51) or abnormal glucose homeostasis (AGH) (impaired fasting glucose, impaired glucose tolerance, or diabetes; n = 25) had their homeostasis model assessment (HOMA) of β-cell function and of insulin sensitivity and hyperbolic product (β-cell function × insulin sensitivity [B × S]) measured. Pancreatic exocrine insufficiency was inferred from pancreatine requirements. Clinical effects of insulin therapy on weight and lung function were recorded.
RESULTS—AGH was observed in 24 and 40% of heterozygous and homozygous subjects, respectively. AGH patients were older than NGT patients (mean ± SD age 29 ± 10 vs. 23 ± 8 years, P = 0.006), and their β-cell function was lower (93 ± 49 vs. 125 ± 51%, P = 0.011). Insulin sensitivity values were comparable in NGT and AGH patients. A lower B × S product was observed in AGH, although it was nonsignificant when adjusted for error propagation. Pancreatic insufficiency was observed in 52 and 100% of heterozygous and homozygous patients (P = 0.001).
CONCLUSIONS—Pre-diabetes and diabetes represent frequent comorbidities in CFTR ΔF508 mutation in the homozygous or heterozygous states. Impairment of insulin secretion, as shown by HOMA, is an important determinant when compared with the magnitude of compensation from insulin sensitivity. Given the high prevalence of abnormal glucose tolerance, screening for (pre-)diabetes is mandatory. Insulin supplementation in diabetic subjects with CFTR ΔF508 mutation seems a rational therapy for consideration, although this does not preclude that therapy directed toward insulin resistance could also interact.
Publisher
American Diabetes Association
Subject
Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference40 articles.
1. Mackie ADR, Thornton SJ, Edenborough FP: Cystic fibrosis-related diabetes. Diabet Med 20: 425–436, 2003
2. Costa M, Potvin S, Berthiaume Y, Gauthier L, Jeanneret A, Lavoie A, Levesque R, Chiasson JL, Rabasa-Lhoret R: Diabetes : a major co-morbidity in cystic fibrosis. Diabetes Metab 31:221–232, 2005
3. Buysschaert M, Hermans MP, Preumont V: Le diabète dans la mucoviscidose: un état des lieux en 2006. In Mises au Point Cliniques d'Endocrinologie, Nutrition, et Métabolisme: Les Editions de Médecine Pratique. Guéritée N, Leclère J, Eds., Paris, Les Editions de Médecine Pratique, 2006, p. 241–254
4. Rowe SM, Miller S, Sorscher EJ: Mechanisms of disease: cystic fibrosis. N Engl J Med 352:1992–2001, 2005
5. Kerem E, Corey M, Kerem B, Rommens J, Markiewicz D, Levison H, Tsui LC, Durie P: The relation between genotype and phenotype in cystic fibrosis: analysis of the most common mutation (ΔF508). N Engl J Med 323:1517–1522, 1990
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献